| Entry |
|
|---|
| Name |
Fludarabine phosphate (JAN/USP);
Fludara (TN) |
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C10H13FN5O7P
|
|---|
| Exact mass |
365.0537
|
|---|
| Mol weight |
365.2117
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Antineoplastic
DG02018 Antimetabolite
DG01958 Nucleic acid derivative, antineoplastic
DG01439 Arabinofuranosyl type antineoplastic
|
|---|
| Remark |
| Therapeutic category: | 4229 |
| Product (DG00685): | D01907<JP/US> |
|
|---|
| Efficacy |
Antineoplastic, Antimetabolite |
|---|
| Disease |
B-cell chronic lymphocytic leukemia [DS: H00005] |
|---|
| Comment |
Active form of prodrug: Fludarabine [DR: D07966]
|
|---|
| Target |
RRM1 [HSA: 6240] [KO: K10807] DNA polymerase RNA polymerase |
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07041 | Antineoplastics - antimetabolic agents |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01B ANTIMETABOLITES
L01BB Purine analogues
L01BB05 Fludarabine
D01907 Fludarabine phosphate (JAN/USP) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Antimetabolites
Fludarabine
D01907 Fludarabine phosphate (JAN/USP)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
422 Antimetabolites
4229 Others
D01907 Fludarabine phosphate (JAN/USP)
Drug groups [BR:br08330]
Antineoplastic
DG02018 Antimetabolite
DG01958 Nucleic acid derivative, antineoplastic
DG01439 Arabinofuranosyl type antineoplastic
DG00685 Fludarabine
D01907 Fludarabine phosphate
Drug classes [BR:br08332]
Antineoplastic
DG02018 Antimetabolite
D01907 Fludarabine phosphate
Target-based classification of drugs [BR:br08310]
Enzymes
Oxidoreductases (EC1)
Ribonucleoside-diphosphate reductase
RRM1
D01907 Fludarabine phosphate (JAN/USP) <JP/US>
Prodrugs [br08324.html]
D01907
Drug groups [BR:br08330]
Antineoplastic
DG02018 Antimetabolite
DG01958 Nucleic acid derivative, antineoplastic
DG01439 Arabinofuranosyl type antineoplastic
DG00685 Fludarabine
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 24
1 C1y C 11.4800 -11.6200
2 C1y C 12.8800 -11.6200
3 C1y C 13.3126 -10.2885
4 O2x O 12.1800 -9.4656
5 C1y C 11.0474 -10.2885
6 O1a O 10.7800 -12.8324
7 O1a O 13.5800 -12.8324
8 N5x N 15.7375 -11.6885
9 C8y C 15.7375 -10.2885
10 N4y N 14.5251 -9.5885
11 C1b C 9.8349 -9.5885
12 O2b O 8.6225 -10.2885
13 C8y C 16.9499 -12.3885
14 N5x N 18.1624 -11.6885
15 C8y C 18.1624 -10.2885
16 C8y C 16.9499 -9.5885
17 N5x N 16.6589 -8.2191
18 C8x C 15.2665 -8.0727
19 N1a N 19.3497 -9.6027
20 X F 16.9499 -13.7900
21 P1b P 7.2225 -10.2885
22 O1c O 5.8225 -10.2885
23 O1c O 7.2225 -8.8901
24 O1c O 7.2225 -11.6899
BOND 26
1 1 2 1
2 2 3 1
3 3 4 1
4 4 5 1
5 1 5 1
6 1 6 1 #Down
7 2 7 1 #Up
8 8 9 1
9 9 10 1
10 3 10 1 #Up
11 5 11 1 #Up
12 11 12 1
13 8 13 2
14 13 14 1
15 14 15 2
16 15 16 1
17 9 16 2
18 16 17 1
19 17 18 2
20 18 10 1
21 15 19 1
22 13 20 1
23 12 21 1
24 21 22 1
25 21 23 2
26 21 24 1
|
|---|
